RxDoctor Payments Data

Rebecca Riley, MD

Internal Medicine · la Jolla, CANPI 1629085964

Payments from drug & device makers

$1,088in general payments, 2019–2025

Across 28 payments — averaging $38.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$158
  • Amgen$141
  • Teva Pharmaceuticals USA, Inc.$124
  • Biohaven Pharmaceuticals, Inc.$120
  • AstraZeneca$120
  • Astellas Pharma US Inc$117
  • plus $308 from 7 others

What the payments were for

  • Food & beverage$1,01994%
  • Education$696%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,088 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$202,803
Medicare patients
703
Services billed
3,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$59,866
OzempicSemaglutide38$47,232
ProliaDenosumab13$21,638
MyrbetriqMirabegron20$19,674
XareltoRivaroxaban11$15,949
JardianceEmpagliflozin11$14,016
SynthroidLevothyroxine Sodium87$6,983
Atorvastatin Calcium684$6,797
PremarinEstrogens, Conjugated12$6,097
Bupropion XlBupropion Hcl102$5,166
Levothyroxine Sodium366$4,507
Ezetimibe106$4,108
Rosuvastatin Calcium257$3,255
Wixela InhubFluticasone Propion/Salmeterol19$3,097
Risedronate Sodium29$2,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$31$65,96378 claims
Novo NordiskOzempic$60$47,23238 claims
AmgenProlia$141$21,63813 claims
Astellas Pharma US IncMyrbetriq$117$19,67420 claims
Johnson & JohnsonXarelto$90$15,94911 claims
AbbVieSynthroid$64$6,98387 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →